BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38060985)

  • 1. Discovery of Dual Function Agents That Exhibit Anticancer Activity via Catastrophic Nicotinamide Adenine Dinucleotide Depletion.
    Fu Y; Huang Y; Zhou C; Li X; Dong G; Huang M; Ding J; Sheng C
    J Med Chem; 2023 Dec; 66(24):16694-16703. PubMed ID: 38060985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
    Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of proqodine A derivatives with antitumor activity targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase.
    Song J; Zou G; Zhao Z; Zhu Y; Xue J; Ao L; Sun H; Hao H; Zhang B; Xu X
    Chin J Nat Med; 2024 Jan; 22(1):75-88. PubMed ID: 38278561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
    Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
    J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
    Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
    Zhang P; Wang W; Guo M; Zhou L; Dong G; Xu D; Sheng C
    Bioorg Med Chem Lett; 2023 Aug; 92():129393. PubMed ID: 37369332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer.
    Wang K; Ye K; Zhang X; Wang T; Qi Z; Wang Y; Jiang S; Zhang K
    J Med Chem; 2023 Jan; 66(1):1027-1047. PubMed ID: 36595482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
    Biniecka P; Matsumoto S; Belotti A; Joussot J; Bai JF; Majjigapu SR; Thoueille P; Spaggiari D; Desfontaine V; Piacente F; Bruzzone S; Cea M; Decosterd LA; Vogel P; Nencioni A; Duchosal MA; Nahimana A
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Potent Nicotinamide Phosphoribosyltransferase Activator for Improving Aging-associated Dysfunctions.
    Yang S; Sun D; Wu Y; Chen S; Guo Y; Li J; Dong G; Sheng C
    J Med Chem; 2024 Mar; 67(5):4120-4130. PubMed ID: 38367219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
    Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
    Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
    J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the NAD
    Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
    Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAD metabolism fuels human and mouse intestinal inflammation.
    Gerner RR; Klepsch V; Macheiner S; Arnhard K; Adolph TE; Grander C; Wieser V; Pfister A; Moser P; Hermann-Kleiter N; Baier G; Oberacher H; Tilg H; Moschen AR
    Gut; 2018 Oct; 67(10):1813-1823. PubMed ID: 28877980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
    Soncini D; Caffa I; Zoppoli G; Cea M; Cagnetta A; Passalacqua M; Mastracci L; Boero S; Montecucco F; Sociali G; Lasigliè D; Damonte P; Grozio A; Mannino E; Poggi A; D'Agostino VG; Monacelli F; Provenzani A; Odetti P; Ballestrero A; Bruzzone S; Nencioni A
    J Biol Chem; 2014 Dec; 289(49):34189-204. PubMed ID: 25331943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage.
    Wang G; Han T; Nijhawan D; Theodoropoulos P; Naidoo J; Yadavalli S; Mirzaei H; Pieper AA; Ready JM; McKnight SL
    Cell; 2014 Sep; 158(6):1324-1334. PubMed ID: 25215490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
    Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
    Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
    Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
    Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing NAD synthesis in muscle via nicotinamide phosphoribosyltransferase is not sufficient to promote oxidative metabolism.
    Frederick DW; Davis JG; Dávila A; Agarwal B; Michan S; Puchowicz MA; Nakamaru-Ogiso E; Baur JA
    J Biol Chem; 2015 Jan; 290(3):1546-58. PubMed ID: 25411251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
    Chen H; Wang S; Zhang H; Nice EC; Huang C
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and their preclinical neuroprotective activity.
    Yao H; Liu M; Wang L; Zu Y; Wu C; Li C; Zhang R; Lu H; Li F; Xi S; Chen S; Gu X; Liu T; Cai J; Wang S; Yang M; Xing GG; Xiong W; Hua L; Tang Y; Wang G
    Cell Res; 2022 Jun; 32(6):570-584. PubMed ID: 35459935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.